定义了1900年至1908年因子VIII残留在因子VIIIa-因子IXa复合物的形成和因子VIIIa活性中的关键作用
Haixia Lv1, Zhe Ming2, Dongmei Wang2
1College of Life Science, State Key Laboratory Cell Differentiation and Regulation and Henan International Joint Laboratory for Pulmonary Fibrosis, Henan Normal University, Xinxiang, Henan, China; Pharmacy College, Xinxiang Medical University, Xinxiang, Henan, China.
Journal of thrombosis and haemostasis : JTH
|December 17, 2025
概括
在因子 (F) VIIIa区域1900-1908中的特定突变显著损害了其辅因子活性和对FIXa的结合亲和力. 这些发现澄清了这些残留物在FXase复合物的稳定性和功能中的作用.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 血液静止研究 血液静止研究
背景情况:
- (F) VIIIa因子对FXase复合体至关重要,催化了FX转化为FXa.
- FVIIIa的1900-1908区域是一个已知的抗体表位,与血友病A有关,但其在FXase活性中的作用尚不清楚.
研究的目的:
- 调查FVIIIa区域1900-1908中的个人残留物对蛋白间亲和力和辅因子活性的影响.
- 阐明该区域在FXase复合体的组装和稳定中的作用.
主要方法:
- 用于产生FVIII轻链 (LC) 变体的局部定向突变发生.
- 再组合的WT和FVIII变异LC被表达,净化,并使用FXa生成试验和光异性质来评估活性,稳定性和亲和力.
- 使用PSIPRED和Phyre2.2预测蛋白质结构.
主要成果:
- 突变D1903A,E1904A,K1906A和S1907A显著增加了FXase和FVIIIa复制的解离常数.
- 降低的光异质性表明FIXa与这些FVIIIa变体的结合亲和力降低.
- D1903A和E1904A突变取消了FIXa介导的FVIIIa稳定,显示了具有或没有FIXa的类似衰变速率.
结论:
- 1900-1908的残留物是FIXa与FVIIIa结合的关键决定因素.
- 这些发现增强了对复杂稳定性和活性的FXase组合和A3域调节的理解.
- 这项研究提供了对血友病A相关的分子机制的洞察,与该区域的突变有关.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K
Fibril-associated Collagen
3.2K
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.2K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262


